AEON Biopharma (AEON) Expected to Post Earnings on Friday

AEON Biopharma (NASDAQ:AEON) will likely be issuing its results on Friday, November 13th. Analysts expect the company to post earnings of ($0.10) per share for the quarter.

AEON Biopharma Trading Down 1.4%

NASDAQ:AEON opened at $0.18 on Wednesday. The firm’s fifty day simple moving average is $0.25 and its 200 day simple moving average is $0.65. AEON Biopharma has a twelve month low of $0.13 and a twelve month high of $1.45. The firm has a market capitalization of $8.94 million, a price-to-earnings ratio of 1.00 and a beta of 0.68.

Insider Buying and Selling at AEON Biopharma

In other AEON Biopharma news, major shareholder Timothy P. Lynch bought 1,150,000 shares of the company’s stock in a transaction dated Wednesday, August 19th. The shares were acquired at an average cost of $0.21 per share, with a total value of $241,500.00. Following the completion of the transaction, the insider owned 6,500,000 shares in the company, valued at $1,365,000. The trade was a 21.50% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 9.40% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several research analysts have commented on AEON shares. HC Wainwright reissued a “buy” rating and issued a $1.20 price objective (down from $5.00) on shares of AEON Biopharma in a research report on Friday, August 14th. Lake Street Capital reaffirmed a “buy” rating and issued a $2.00 target price (up from $1.00) on shares of AEON Biopharma in a research report on Thursday, October 1st. Finally, Laidlaw assumed coverage on AEON Biopharma in a research note on Wednesday, September 9th. They issued a “buy” rating and a $1.80 target price for the company. Three equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $1.67.

About AEON Biopharma

AEON Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing botulinum toxin-based therapies for therapeutic, rather than primarily aesthetic, applications. Its lead product candidate, ABP-450, is an investigational botulinum toxin type A complex being studied for the treatment of neurological and other medical conditions. AEON Biopharma has advanced ABP-450 in clinical development for conditions including chronic migraine and cervical dystonia, a disorder involving involuntary neck-muscle contractions.